Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jun 12;9:1300. doi: 10.3389/fimmu.2018.01300

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2018 El Kholy, Freire, Chen and Van Dyke.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Osteoclast differentiation pathway perturbation after stimulation with interleukin (IL)-6 with or without resolvin E1 (RvE1). Using Illumina’s iPathwayGuide application, a significant perturbation in the osteoclast differentiation pathway was noted after stimulation of osteoblasts with IL-6. Upregulation of IL-1 lead to promotion of downstream signaling affecting the MAPK and NFκB signaling pathways leading to upregulation of osteoclast differentiation. After treatment with RvE1, downregulation of STAT1 led to inhibition of downstream signaling affecting the MAPK and NFκB signaling pathways leading to downregulation of osteoclast differentiation.

Osteoclast differentiation pathway perturbation after stimulation with interleukin (IL)-6 with or without resolvin E1 (RvE1). Using Illumina’s iPathwayGuide application, a significant perturbation in the osteoclast differentiation pathway was noted after stimulation of osteoblasts with IL-6. Upregulation of IL-1 lead to promotion of downstream signaling affecting the MAPK and NFκB signaling pathways leading to upregulation of osteoclast differentiation. After treatment with RvE1, downregulation of STAT1 led to inhibition of downstream signaling affecting the MAPK and NFκB signaling pathways leading to downregulation of osteoclast differentiation.